TYME

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Resolute Forest Products Inc. (NYSE - RFP), Meridian Bioscience, Inc. (Nasdaq - VIVO), TYME Technologies (Nasdaq - TYME)

Retrieved on: 
Wednesday, July 13, 2022
Domtar, Consortium, Single Resolution Board, Contingent value rights, Company, Brodsky, GLOBE, Nasdaq, Security (finance), Syros, Meridian, TYME

BALA CYNWYD, Pa., July 13, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., July 13, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement and plan of merger, Resolute will be acquired by The Paper Excellence Group, through its wholly-owned subsidiary Domtar Corporation (Domtar).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME

Retrieved on: 
Wednesday, July 6, 2022
Class Action Lawsuit, Professional Services, Legal, KSF, Sale, LLC, Company, Nasdaq, TYME, Syros

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to Syros Pharmaceuticals, Inc. (NasdaqGS: SYRS).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Retrieved on: 
Tuesday, July 5, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Patient, Research, Register, COVID-19, Cancer, Company, Hematology, Roche, Nature, NDA, Security (finance), RARA, Securities Act of 1933, Achievement, Securities Exchange Act of 1934, Gene, Intellectual property, Prospectus, Pancreatic cancer, Proxy, Breast, SEC, Registration statement, Risk, Twitter, Forward-looking statement, LinkedIn, Acute promyelocytic leukemia, Hematological Cancer Research Investment and Education Act, Failure, Goal, AML, Sarcoma, Acute myeloid leukemia, Nasdaq, NASDAQ, Board, Review, Annual report, BRAF, LLP, Sale, U.S. Securities and Exchange Commission, Form, PIPE, Azacitidine, Prostate, Wilmer Cutler Pickering Hale and Dorr, CDK7, Government, Safety, Venetoclax, APL, Arsenic trioxide, Program, Genome, Director, Pharmaceutical industry, Bank, Management, Holding company, TYME, Piper, Syros

Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94.

Key Points: 
  • Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94.
  • The team at Syros shares our unwavering commitment to develop medicines that make a profound difference in patients lives.
  • In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYMEs expected net cash at closing and TYME stockholders are expected to receive approximately 0.4312 shares of Syros common stock for each share of TYME common stock.
  • The Registration Statement and the Joint Proxy Statement/Prospectus will contain important information about Syros, TYME, the transactions and related matters.

TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results

Retrieved on: 
Wednesday, May 25, 2022
Cancer, Breast, Risk, Company, Disease, Consultant, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Nasdaq, Breast cancer, Prostate, Hematological Cancer Research Investment and Education Act, Uncertainty, Cell death, Clinical trial, COVID-19, Research, Net, Forward-looking statement, Compliance, Board, Board of directors, OASIS, Sarcoma, Lung, GAAP, LinkedIn, Twitter, Oxidative stress, GLOBE, Annual report, SARS, Pharmaceutical industry, Medical imaging, TYME, Facebook

BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.

Key Points: 
  • BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.
  • As of the quarter ended March 31, 2022, the Company had approximately $84.0 million in cash and marketable securities, compared to $92.0 million as of the quarter ended December 31, 2021.
  • TYMEs operational cash burn rate for the fourth quarter of fiscal year 2022 was $7.7 million compared to $4.5 million for the third quarter and $5.2 million for the fourth quarter of fiscal year 2021.
  • These financial measures are presented on a basis other than in accordance with U.S. generally accepted accounting principles ("Non-GAAP Measures").

TYME Technologies, Inc. Announces Exploration of Strategic Options

Retrieved on: 
Tuesday, March 29, 2022
Evotec, Company, Private Securities Litigation Reform Act, Cancer, Clinical trial, Risk, Lung, Cell death, MOA, Forward-looking statement, Sarcoma, Board, Compliance, Prostate, Breast, AACR, SEC, Strategic planning, Biotechnology, Research, American Association, Oxidative stress, Board of directors, Methoxsalen, U.S. Securities and Exchange Commission, Learning, MPS, Association, American Association for Cancer Research, Phenytoin, Nasdaq, COVID-19, Sirolimus, GLOBE, Uncertainty, Annual report, Breast cancer, Patient, Disease, Phase, Pharmaceutical industry, TYME

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.

Key Points: 
  • BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
  • Notwithstanding the discontinuation of its most advanced clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders.
  • TYME believes that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moelis & Company LLC.
  • The goal of the strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our stockholders.

TYME Technologies, Inc. Announces Changes to its Board of Directors

Retrieved on: 
Friday, March 25, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Private Securities Litigation Reform Act, Risk, Lead, Cell death, NYSE, Hotel manager, Prostate, Research, SEC, Twitter, Hematological Cancer Research Investment and Education Act, Intellectual property, OraSure Technologies, Nasdaq, Solution, Annual report, Disease, Sarcoma, Drug development, WST, Novartis, Breast, Schering-Plough, Industry, Director, U.S. Securities and Exchange Commission, Dartmouth College, Uncertainty, Cancer, Clinical trial, Lung, Forward-looking statement, Board, Communication, Board of directors, Rutgers University, Company, Business development, Marketing, LinkedIn, SARS, Compliance, Oxidative stress, HIV/AIDS, Michels, COVID-19, MBA, Presidential Advisory Council on HIV/AIDS, Breast cancer, Johnson & Johnson, Pharmaceutical industry, Management, Medical imaging, Chemistry, TYME, Facebook, TYME TECHNOLOGIES, INC., SM-88

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced changes to its Board of Directors.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced changes to its Board of Directors.
  • The Company is pleased to announce that Christine D. Baker has been appointed to TYMEs Board of Directors.
  • Mr. Michels, who currently serves on TYMEs Board of Directors as Lead Independent Director, will assume the role of Chairman of the Board.
  • Mr. Michels, who has served on TYMEs Board of Directors since October 2018, has over 39 years of experience in the healthcare industry.

TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Wednesday, March 9, 2022
Nasdaq, AACR, Oxidative stress, Lung, American Association for Cancer Research, Twitter, Cell death, ORR, Methoxsalen, Risk, Compliance, Company, Breast, Prostate, Research, Department, Sirolimus, Sarcoma, Â, Clinical trial, Hematological Cancer Research Investment and Education Act, MedStar Health, Annual report, U.S. Securities and Exchange Commission, Cancer, Private Securities Litigation Reform Act, Georgetown University, GLOBE, Doctor of Philosophy, Breast cancer, Patient, Neoplasm, American Association, OASIS, Uncertainty, Population, COVID-19, MPS, Phenytoin, Disease, Toxicity, Association, Poster, SARS, Forward-looking statement, LinkedIn, ER, Pharmaceutical industry, Medical imaging, Facebook, TYME

BEDMINSTER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the availability of the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer,” which was submitted by researchers from Georgetown University. The abstract will be presented by Dr. Ayesha Shajahan-Haq at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA. Dr. Shajahan-Haq, PhD is an Assistant Professor in the Department of Tumor Biology at Georgetown University, and her research focuses on resistance mechanisms in breast cancer.

Key Points: 
  • The abstract will be presented by Dr. Ayesha Shajahan-Haq at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.
  • Dr. Shajahan-Haq, PhD is an Assistant Professor in the Department of Tumor Biology at Georgetown University, and her research focuses on resistance mechanisms in breast cancer.
  • In earlier studies, SM-88 showed encouraging efficacy in breast cancer patients, including patients with HR+/HER2- disease.
  • We are excited to see more preclinical data to deepen our understanding of SM-88's utility in this setting.

TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

Retrieved on: 
Friday, February 11, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Oxidative stress, Webcast, Uncertainty, Cancer, GAAP, Risk, Cell death, Company, Private Securities Litigation Reform Act, Forward-looking statement, Lung, SARS, Nasdaq, Consultant, Annual report, Breast, Event, Compliance, Hematological Cancer Research Investment and Education Act, LinkedIn, Breast cancer, U.S. Securities and Exchange Commission, Twitter, Prostate, Clinical trial, Disease, Sarcoma, Research, COVID-19, Investor, Medical imaging, Pharmaceutical industry, Facebook, TYME, TYME Technologies, Inc., SM-88, TYME TECHNOLOGIES, INC., SM-88

Adjusted net loss and adjusted net loss per share as presented in this report are non-GAAP measures.

Key Points: 
  • Adjusted net loss and adjusted net loss per share as presented in this report are non-GAAP measures.
  • These financial measures are presented on a basis other than in accordance with U.S. generally accepted accounting principles ("Non-GAAP Measures").
  • These Non-GAAP Measures should be considered a supplement to, not a substitute for, or superior to, the corresponding financial measures calculated in accordance with GAAP.
  • Our definitions of adjusted net loss and adjusted loss per share may not be comparable to similar measures reported by other companies.

TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

Retrieved on: 
Thursday, January 27, 2022
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Science, Oncology, Other Science, LinkedIn, Investor, Breast, SEC, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Q&A, Twitter, Uncertainty, Company, Hematological Cancer Research Investment and Education Act, Annual report, Cancer, Prostate, Sarcoma, Event, Webcast, Facebook, TYME

The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com , and will be archived for 90 days following the event.

Key Points: 
  • The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com , and will be archived for 90 days following the event.
  • Management will address both live questions and those submitted in advance via email to [email protected] .
  • The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022.
  • In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties.

TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Retrieved on: 
Wednesday, January 26, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, COVID-19, Survival, Risk, Lung, Methoxsalen, MSC, Clinical trial, Uncertainty, U.S. Securities and Exchange Commission, Arm, Patient, Prostate, Annual report, Population, FOLFIRINOX, Phenytoin, Hematological Cancer Research Investment and Education Act, Twitter, Private Securities Litigation Reform Act, Research, Cancer, List of commonly used taxonomic affixes, Pancreatic cancer, Breast, Breast cancer, LinkedIn, MPS, Company, Cell death, Oxidative stress, Protein-bound paclitaxel, Compliance, MD, Learning, Sarcoma, Disease, Nasdaq, Pancreatic Cancer Action Network, Forward-looking statement, Gemcitabine, Pharmaceutical industry, Mobile phone, Medical imaging, Facebook, TYME, TYME Technologies, Inc., SM-88, TYME TECHNOLOGIES, INC., SM-88

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.

Key Points: 
  • TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC.
  • The Precision Promise trial is an adaptive randomized Phase 2/3 trial in mPDAC for patients treated in both first-line and second-line therapies.
  • Given pancreatic cancers high mortality rate, we wanted to make a difference in the lives of these patients.
  • A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer.